Bednarek C, Nguyen T V F, Puyraveau M, Bonnet É, Lescut N, Azélie C, Miny J, Mauvais O, Maurina T, Tochet F, Bosset J-F, Thariat J, Sun X S
Department of radiotherapy, CHU de Besançon, 2, boulevard Fleming, 25030 Besançon, France.
Department of radiotherapy, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Cancer Radiother. 2017 Feb;21(1):21-27. doi: 10.1016/j.canrad.2016.07.103. Epub 2016 Dec 27.
To report on patterns of relapse following implementation of intensity-modulated radiotherapy and subsequent changes in practice in a tertiary care centre.
Between 2008 and 2011, 188 consecutive patients (mean age 59 years old) received intensity-modulated radiotherapies with curative intent for squamous cell carcinomas of the oral cavity (17.5%), oropharynx (43%), hypopharynx (21%), larynx (14%), sinonasal cavities (6%), nasopharynx (1.5%) at the university hospital of Besançon. There were stage I and II 9%, III 24.5%, IV 66.5%. One hundred and thirty-eight underwent exclusive intensity-modulated radiotherapy, 50 underwent postoperative intensity-modulated radiotherapy, 174 had concurrent chemotherapy, 57 had induction chemotherapy. Dynamic intensity-modulated radiotherapy with static fields was performed for all patients using sequential irradiation in 174 patients and simultaneous integrated boost irradiation in 14 patients.
With a median follow-up was 27.5 months, there was 79% of locoregional failures occurred in the 95% isodose. Two-year overall survival, disease-free, local failure-free and locoregional failure-free survival rates were73%, 60%, 79% and 72%, respectively. Prognostic factors for disease-free survival were stage (IV vs. I-III) with a relative risk of 1.7 [1.1-2.8] (P=0.02) and T stage with 1.6 [1.04-2.5] (P=0.03).
The current series showed similar patterns of failure as in other tertiary care centres. We did not identify intensity-modulated radiotherapy specific relapse risks.
报告在三级医疗中心实施调强放射治疗后的复发模式以及随后的实践变化。
2008年至2011年期间,188例连续患者(平均年龄59岁)在贝桑松大学医院接受了以治愈为目的的调强放射治疗,治疗口腔鳞状细胞癌(17.5%)、口咽癌(43%)、下咽癌(21%)、喉癌(14%)、鼻窦腔癌(6%)、鼻咽癌(1.5%)。其中Ⅰ期和Ⅱ期占9%,Ⅲ期占24.5%,Ⅳ期占66.5%。138例接受单纯调强放射治疗,50例接受术后调强放射治疗,174例接受同步化疗,57例接受诱导化疗。所有患者均采用静态野动态调强放射治疗,174例患者采用序贯照射,14例患者采用同步整合加量照射。
中位随访时间为27.5个月,95%等剂量线内发生79%的局部区域失败。两年总生存率、无病生存率、局部无失败生存率和局部区域无失败生存率分别为73%、60%、79%和72%。无病生存的预后因素为分期(Ⅳ期与Ⅰ - Ⅲ期),相对风险为1.7 [1.1 - 2.8](P = 0.02)以及T分期,相对风险为1.6 [1.0–2.5](P = 0.03)。
本系列研究显示的失败模式与其他三级医疗中心相似。我们未发现调强放射治疗特有的复发风险。